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Purpose: Dopamine (DA), which does not cross the blood-brain barrier, has central
and behavioral effects when administered via the nasal route. Neither the mechanisms
of central action of intranasal dopamine (IN-DA), nor its mechanisms of diffusion
and transport into the brain are well understood. We here examined whether IN-DA
application influences dopamine transporter (DAT) binding in the dorsal striatum and
assessed the extent of binding in relation to motor and exploratory behaviors. We
hypothesized that, based on the finding of increased extracellular DA in the striatum
induced by application of IN-DA, binding of [123I]FP-CIT to the DAT should be decreased
due to competition at the receptor.
Methods: Rats were administered 3 mg/kg IN-DA and vehicle (VEH), with IN-DA
injection either preceding or following VEH. Then motor and exploratory behaviors
(traveled distance, velocity, center time, sitting, rearing, head-shoulder motility,
grooming) were assessed for 30 min in an open field prior to administration of [123I]FP-
CIT. DAT binding after IN-DA and VEH was measured with small animal SPECT 2 h
following administration of the radioligand.
Results: (1) After IN-DA application, striatal DAT binding was significantly lower as
compared to VEH, indicating that the nasally delivered DA had central action and
increased DA levels comparable to that found previously with L-DOPA administration;
and (2) DAT binding in response to intranasal VEH was lower when IN-DA application
preceded VEH treatment. This finding is suggestive of Pavlovian conditioning
of DA at the level of the DAT, since the DA treatment modified (decreased)
the binding in response to the subsequent VEH treatment. VEH treatment also
reduced motor and exploratory behaviors more when applied before, as compared
to when it followed IN-DA application, also indicative of behavioral Pavlovian
conditioning akin to that found upon application of various psychostimulant drugs.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 1 April 2016 | Volume 10 | Article 80
de Souza Silva et al. Intranasal Dopamine
Conclusions: The results: (a) demonstrate a direct central action of intranasally applied
DA on the DAT in the dorsal striatum, indicating enhanced DA availability; and (b) provide
first evidence of a Pavlovian conditioned DA response at the DAT. The latter results have
relevance to understanding neurochemical mechanisms that underlie placebo action in
the treatment of Parkinsonian patients.
Keywords: dopamine, intranasal administration, dopamine transporter, small animal SPECT, Pavlovian
conditioning, placebo
INTRODUCTION
Deficiencies of dopamine (DA) function play a major role in
the pathophysiology of various neurological and psychiatric
conditions (for review, see Nikolaus et al., 2007), and also
correlate with aging-related deficits in cognitive and emotional
processes (for review, see Li and Rieckmann, 2014). DA is
known to promote learning andmemory (for review, seeMyhrer,
2003) and its action has been strongly implicated in the neural
mechanisms of information storage and retrieval (Muzzio et al.,
2009).
Since DA does not cross the blood brain barrier, its
application via the nasal route may be a promising alternative
for targeting central nervous system DA receptors (Tayebati
et al., 2013). There is evidence that intranasal dopamine (IN-DA)
bypasses the blood-brain barrier and thus, can be transported
directly from the nasal mucosa along the olfactory pathway into
the brain. Application of [3H]-DA into a nostril of mice led
to higher DA counts in the ipsilateral olfactory bulb (27 times
higher than in the contralateral bulb) and high amounts in the
lateral olfactory tract, but not in other brain regions (Dahlin
et al., 2000). Similar results were found in rats (Dahlin et al.,
2001). Application of IN-DA into the nostrils of anesthetized
rats was also shown to increase extracellular DA in the dorsal
and ventral striatum for at least 2 h by as much as 250%
(de Souza Silva et al., 2008). In the freely moving rat, IN-
DA influenced motor activity and exerted antidepressant-like
effects (Buddenberg et al., 2008). In aged rats, IN-DA was
found to restore deficient object-place memory (Trossbach
et al., 2014). In the 6-hydroxydopamine (6-OHDA)-lesion
model of Parkinson’s disease (PD), behavioral asymmetries
were attenuated by chronic administration of IN-DA (Pum
et al., 2009). Moreover, IN-DA reduced behavioral hyperactivity
and improved non-selective and selective attention in a rat
model of attention-deficit hyperactivity disorder (ADHD), when
applied during the prepuberal period (Ruocco et al., 2009, 2014).
Intranasal [3H]-DA was also found in the cerebrospinal fluid of
monkeys 15 min post-application (Kumar et al., 1976). Neither
the route of transportation of IN-DA into the brain, nor its
mechanisms of central action are well understood.
We have recently shown that radioligand binding to
the striatal dopamine transporter (DAT) is reduced by
intraperitoneal (i.p.) application of the DA precursor L-DOPA
and that the reduction of DAT binding is related to alterations
of motor and exploratory behaviors in the open field (Nikolaus
et al., 2013, 2014). In the present study, we jointly assessed
neostriatal DAT binding and motor/exploratory behaviors
after intranasal application of DA and vehicle (VEH). The
rationale was to determine: (a) whether the nasal application
of DA influences binding to DAT in the striatum, and
thus, to provide information as to its action in the brain;
and (b) to assess whether differences in DAT binding
are related to differences in various parameters of motor
and exploratory activity. For this purpose the animals were
tested for 30 min in an open field after application of
IN-DA and VEH.
The application of psychostimulant drugs, such as
amphetamine and cocaine, is well known to result in Pavlovian-
like conditioned behavioral activation and DA sensitization
in rodents (Carey and Damianopoulos, 1992; Carey and Gui,
1998; Carey et al., 2005). Even a single drug application can
result in long-lasting Pavlovian conditioning (McDougall
et al., 2014). In PD patients, conditioned DA release in the
striatum of PD patients to placebo treatment was reported
using competition for [11C] raclopride binding as measured
by positron emission tomography (de la Fuente-Fernández
et al., 2001; Lidstone et al., 2010). Therefore, in order to
assess the possibility of conditioned changes in DA binding,
we employed an experimental design in which each rat was
treated with both IN-DA and VEH, five animals with IN-DA
preceding VEH, and seven with the order reversed. This
procedure permits a comparison of the extent of DAT binding
not only between IN-DA and VEH, but also depending on the
order in which they were administered. We hypothesized that
IN-DA administered prior to VEH would lead to a Pavlovian
conditioned increase in DA release to VEH administration
and consequently to lower binding of the radioligand
to the DAT.
MATERIALS AND METHODS
Animals
We used 12 adult male Wistar rats (TVA, Heinrich-Heine
University, Düsseldorf, Germany), weighing 398± 58 g (mean±
standard deviation [SD]). Animals were maintained in standard
makrolon cages (59 × 38 × 20 cm3 animals per cage) in a
climate cabinet (Scantainer, Scanbur BK, Karslunde, Denmark;
temperature: 20◦C; air humidity: 70%) with an artificial light-
dark cycle (lights on at 6:00 a.m.; lights off at 6:00 p.m.)
and food and water freely available. The study was approved
by the regional authority and carried out in accordance with
the ‘‘Principles of laboratory animal care’’ (NIH publication
No. 86–23, revised 1985) and the German Law on the Protection
of Animals.
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Each rat underwent 2 trials in randomized order, which were
at least 7 days apart. Each trial consisted of: (a) pharmacological
challenge with IN-DA or IN-VEH; (b) assessment of behavior
in the open-field for 30 min; (c) application of the radioligand
30 min post-challenge; and (d) DAT imaging with small animal
SPECT 150 min post-challenge.
SPECT Camera
The small animal tomograph (‘‘TierSPECT’’) was described in
detail elsewhere (Schramm et al., 2000). For 123I, tomographic
resolution and sensitivity amount to 3.4 mm and 16 cps/MBq,
respectively. Data were acquired for 60 min in a step-and-
shoot mode over a circular orbit in angular steps of 6◦
(60 projections, 60 s/projection). Data were reconstructed with
an iterative ordered-subset-expectation-maximization algorithm
(3 iterations, 4 subsets/iteration). No post-filtering procedure
was applied. An attenuation correction of 0.11 cm−1 was
implemented assuming a uniformly attenuating medium.
DA Treatment
Each rat received treatment with IN-DA and its VEH in
randomized trials (IN-DA first in order, n = 5; VEH first in order,
n = 7, with at least 7 days between trials). DA hydrochloride
(Sigma-Aldrich, Taufkirchen, Germany) was applied in a dose
of 3 mg/kg. The crystalline DA was suspended in a volume of
10 µl of gel composed of a viscous castor oil mixture (M&P
Pharma, Emmetten, Switzerland) immediately before usage. It
was kept on ice throughout the experiment and protected from
light. Per nostril, 5 µl of either DA or VEH was applied with an
applicator pipette for viscous liquids (Microman, Gilson, Villiers
le Bel, France) and corresponding tips (CP10 Tips, Gilson,
Villiers le Bel, France). Drug administration was performed
in awake animals over 8 s per nostril with an application
depth of 2 mm.
Behavioral Studies
Immediately after the application of IN-DA or VEH, rats were
placed into the center of an apparatus (openfield dimensions:
45 × 45 × 56 cm3) with a topunit equipped with light-
emitting diodes and a charge-coupled device (CCD) camera
(Phenotyperr, Noldus Information Technology, Wageningen,
Netherlands) situated on the ceiling of the apparatus. Behaviors
were assessed with EthoVision XT 8 (Noldus Information
Technology, Wageningen, The Netherlands) in blocks of 10 min
for a total of 30 min. EthoVision XT 8 automatically determined
the distance in cm traveled by the rat and the velocity of
locomotion (cm/s) as measures of motor activity as well as the
time (s) spent in the center of the open field (a quadratic area
of 15 × 15 cm) and the frequency (n) of entries as measures
of anxiety. In addition, the durations (s) and frequencies
(n) of the following motor and exploratory behaviors were
extracted from video recordings by a blinded observer: sitting
(total: with or without head-shoulder motility); rearing (freely
standing or leaning against the wall) as measure of both motor
and exploratory activity; head-shoulder motility (movements of
head and shoulders while the animal is sitting) as measure of
exploratory activity not associated with locomotion; grooming
(licking of fur and paws and scratching). Sitting without any
motility was computed from the acquired data (defined as sitting
minus head-shoulder motility). The animals were not handled
prior to the behavioral studies to adhere to the procedure used
in a DAT binding study using L-DOPA (Nikolaus et al., 2013,
2014).
In Vivo Imaging of DAT Binding
Thirtymin after IN-DA or VEH application, the animals received
i.p. injections of pentobarbital (Narcoren, Merial GmbH,
Hallbergmoos, Germany; concentration: 0.5 ml in 1 ml Ringer’s
solution; dose: 2 ml/kg). Then 27 ± 4 MBq [123I]-FP-CIT
(DATSCAN, GE Healthcare, München, Germany; concentration
range, 0.07–0.13 µg/ml, specific activity range, 2.5–4.5 × 1014
Bq/mmol at reference [REF] time) were administered into the
lateral tail vein with a winged infusion needle set (Venofix,
B. Braun, Melsungen, Germany and Vacutainer, Beckton,
Dickinson & Co, Plymouth, UK). The tube was rinsed with 1 ml
0.9% saline. The total injection volume amounted to 1.3 ml.
Since the equilibrium of [123I]FP-CIT binding is reached at
2 h post-injection with the ratio of specific to non-specific striatal
uptake remaining stable over the following 2 h (Booij et al.,
1997), SPECT measurements were started 2 h after radioligand
application. Since SPECT measurements were conducted over
1 h, animals were kept under anesthesia for a total of 3 h.
Evaluation of DAT Imaging Studies
Imaging data were evaluated using the Multi-Purpose-Imaging-
Tool (MPI-Tool V3.29, Advanced Tomo Vision GmbH, Kerpen,
Germany) as previously described (e.g., Nikolaus et al., 2013,
2014). Briefly, maximum striatal count rates (counts/pixel)
were determined on coronal slices by defining a circular
region covering an area of 1.5 mm2 (Figure 1A). Cerebellar
REF count rates (counts/pixel) were obtained by defining
an elliptic region (area, 7 mm2 comprising 53 pixels) on
coronal slices approximately 15 mm posterior to the frontal
cortex corresponding anatomically to the rat cerebellum
(Figure 1A). Left and right striatal counts rates were averaged.
Striatocerebellar ratios were computed as estimates for the
binding potential (Laruelle et al., 1994).
Statistical Analysis
DAT Binding
Neostriatal DAT binding as well as motor/exploratory behaviors
(traveled distance [cm], velocity [cm/s], duration [s], mean
duration [s], and frequency [n] of entries into the center of the
open field, sitting with head-shoulder motility, sitting without
motility, rearing, head-shoulder motility while sitting, and
grooming) were compared between IN-DA and VEH conditions
for all animals (n = 12) as well as for the animals treated with
IN-DA first in order (n = 5) and for the animals treated with
IN-DA second in order (n = 7).
Firstly, DAT binding after IN-DA was compared to DAT
binding after VEH (n = 12, t test for paired samples, two-tailed,
α = 0.05).
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FIGURE 1 | (A) ROI definition on coronal slices. (B) Coronal [123 I]FP-CIT images of a rat head after challenge with intranasal dopamine (IN-DA; left) and vehicle
(VEH; right). The reduction in striatal dopamine transporter (DAT) binding after IN-DA is clearly visible.
In order to assess the interaction effect of treatment (VEH
vs. IN-DA) and order (VEH applied before or after IN-DA) on
striatocerebellar DAT binding, two further pairwise comparisons
(t tests for independent samples, two-tailed, α = 0.05) were
performed: (1) DAT binding scores after IN-DA of the animals
treated with IN-DA first (n = 5) were compared to the DAT
binding scores after IN-DA of the animals treated with VEH first
(n = 7); (2) the DAT binding scores after VEH of the animals
treated with VEH first (n = 7) were compared to the DAT
binding scores after VEH of the animals treated with IN-DA first
(n = 5).
In order to minimize between-subject variance for each
comparison (Loftus and Masson, 1994), DAT binding scores
in each sample (n = 12, n = 5, n = 7) were adjusted in
the following manner: (1) DAT binding scores after IN-DA
and VEH were averaged for each sample (n = 12, n = 5,
n = 7); (2) DAT binding scores after IN-DA and VEH
were averaged for each rat; (3) the mean DAT binding score
obtained for each rat was subtracted from the mean DAT
binding score obtained for each sample (n = 12, n = 5, and
n = 7), thus producing an adjustment factor (i.e., individual
deviation from the general level of the dependant variable
over both treatments); (4) finally, the adjustment factor was
added to each individual DAT binding score in the samples
(n = 12, n = 5, n = 7), yielding adjusted samples with equally
distributed between-subject differences. From the resulting
six samples of adjusted scores (DAT binding scores after
IN-DA for n = 12, n = 5, and n = 7; DAT binding scores
after VEH for n = 12, n = 5, and n = 7), means and
adjusted 95% confidence intervals were computed. The means
and adjusted 95% confidence intervals were plotted using
SigmaPlot 12.0 (Systat Software GmbH, Erkrath, Germany).
The error bars illustrate the pattern of difference between
treatment conditions across the samples (n = 12, n = 5,
n = 7).
Behavior in the Open Field
The interaction effect of treatment and order on behaviors
observed in the open field was explored using multivariate
simple effects analysis within the framework of the general linear
model (3 × 2 within-subject design; within-subject factors: time
[0–10 min, 11–20 min, 21–30 min] and treatment [IN-DA vs.
VEH]). The behavioral measures included traveled distance,
velocity, duration, mean duration and frequency of entries into
the center of the open field, as well as duration, mean duration
and frequency of the following behaviors: grooming, rearing,
head-shoulder motility, sitting with and without head-shoulder
motility. The calculations were performed separately for the
whole sample (n = 12), for the animals treated with IN-DA before
VEH (n = 5), and for the animals treated with VEH before IN-DA
(n = 7). The within-subject effect of treatment (IN-DA vs. VEH)
and the corresponding F statistic were computed separately for
each time bin (0–10 min, 11–20 min, 21–30 min).
Apart from the simple effects analysis, in order to minimize
between-subject variance in the error term, an adjustment
procedure analog to the one performed on DAT binding scores
was executed: (1) for each time bin, behavioral scores after
IN-DA and VEH were averaged for each sample (n = 12, n = 5,
n = 7); (2) for each time bin, behavioral scores after IN-DA
and VEH were averaged for each rat; (3) the mean behavioral
score obtained for each rat in each time bin was subtracted from
themean obtained for each sample (n = 12, n = 5, and n = 7) in the
respective time bin thus yielding an adjustment factor (one value
per subject per time-bin); (4) the adjustment factor was added to
each individual score (for each time-bin separately). Finally, for
each adjusted sample (per treatment per time-bin: n = 12, n = 5,
and n = 7), means and adjusted 95% confidence intervals were
computed.
In order to illustrate the pattern of within-subject differences
between treatments (IN-DA vs. VEH) as a function of order of
application (across the samples: n = 12, n = 5, and n = 7), the
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means and adjusted 95% confidence intervals were plotted using
SigmaPlot 12.0.
Correlation Between Neostriatal DAT Binding and
Behavior
In order to explore the relationship between the level of
DAT binding and the behaviors observed in the open field,
we computed two-tailed Spearman’s correlation coefficients
(α = 0.05) between the striatocerebellar ratio and the behaviors
exhibited by the animals in each treatment condition (VEH
or IN-DA). Bias corrected and accelerated bootstrap 95%
confidence intervals for the correlation coefficients are also
reported.
All calculations were performed using IBM SPSS Statistics 22
(IBM Corporation, Armonk, USA).
RESULTS
DAT Binding
Figure 1B shows characteristic images of [123I]FP-CIT
accumulations after treatment with IN-DA and VEH in the
same rat. Striatal [123I]FP-CIT accumulations were markedly
reduced following challenge with IN-DA.
REF Count Rates
After IN-DA and VEH, cerebellar radioactivity concentrations
(data not shown) amounted to 744 ± 182 counts/pixel (mean
± SD) and 628 ± 217 counts/pixel. No significant differences
between conditions were obtained.
All Rats Irrespective of Treatment Order (n = 12)
After application of IN-DA, maximum striatocerebellar ratios
were reduced relative to VEH (paired t test: p = 0.008).
Comparison Between Order of Treatment
Striatocerebellar ratios after IN-DA in animals treated with
IN-DA first in order were not significantly different from
striatocerebellar ratios after IN-DA in animals treated with VEH
first in order.
Striatocerebellar ratios after VEH in animals treated with
IN-DA first in order, were lower relative to striatocerebellar
ratios after VEH in animals treated with VEH first in order
(independent t test: p = 0.039).
After adjustment of the DAT binding scores in order to reduce
between-subject variance within each sample, the resulting
means and adjusted 95% confidence intervals amounted to the
following values: (1) for all animals (n = 12): MVEH = 2.44 [95%
CI: 2.29, 2.58], MIN−DA = 2.01 [95% CI: 1.86, 2.15]; (2) for
animals treated with IN-DA first (n = 5): MVEH = 2.11 [95% CI:
1.95, 2.27], MIN−DA = 1.84 [95% CI: 1.68, 2.00]; (3) for animals
treated with VEH first (n = 7):MVEH = 2.67 [95% CI: 2.42, 2.93],
MIN−DA = 2.13 [95% CI: 1.87, 2.38]. The data are depicted in
Figure 2.
Differences Between Means
The pattern of within-subject differences in the present study is
represented by the distance between the points on the Y-axis.
FIGURE 2 | Striatocerebellar ratios after IN-DA and VEH in all animals
(n = 12), in animals treated with IN-DA first (n = 5) and in animals
treated with VEH first (n = 7). Means, adjusted 95% CI of means.
The distance in question, representing the effect of the treatment
on DAT binding, visibly differs as a function of order: a small
difference was obtained from the five animals treated with
IN-DA before VEH, while a larger one resulted from the seven
animals treated with VEH before IN-DA. When the treatments
were compared for all subjects independently of treatment order
(n = 12), the difference was still present, albeit reduced in relation
to n = 7 (VEH before IN-DA).
Differences Between Adjusted Error Bars
Possible effect of the treatment in future replications of the
experiment can be inferred from the error bars. The trend of
higher DAT binding after VEH is present independently of
the order of treatment. However, the differences between the
conditions were smaller in animals treated with IN-DA before
VEH. The overlapping error bars for n = 5 suggest that it is
unlikely to find a significant difference between DAT binding
scores when IN-DA treatment precedes VEH. As to the animals
treated with VEH first, their difference scores (VEH minus
IN-DA) were larger, hence the larger difference between means.
However, the trend among them was also more variable, as the
larger (less precise) confidence intervals suggest.
Behavior
All Rats Irrespective of Treatment Order (n = 12)
The simple effects analysis showed no significant effect of
treatment on either behavioral parameter.
Rats Treated with IN-DA Before VEH (n = 5)
The simple effects analysis revealed no effect of treatment on
behavior.
Rats Treated with VEH Before IN-DA (n = 7)
The IN-DA application significantly decreased the following
behaviors compared to VEH:
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- Traveled distance [cm] (F(1,6) = 24.4, p = 0.003,MVEH = 1424.4
[95% CI: 1335.1, 1513.8], MIN−DA = 1063.8 [95% CI: 974.5,
1153.1]) and velocity [cm/s] F(1,6) = 26.9, p = 0.002,MVEH = 2.4
[95% CI: 2.3, 2.6] in time bin 11–20 min.
- Frequency of entries into the center of the open field [n]
(F(1,6) = 34, p = 0.001, MVEH = 6.9 [95% CI: 5.9, 7.9],
MIN−DA = 2.1 [95% CI: 1.2, 3.1]) in time bin 0–10 min.
- Duration of rearing [s] (F(1,6) = 6.2, p = 0.047, MVEH = 95.7
[95%CI: 80.2, 111.3],MIN−DA = 64 [95%CI: 48.5,79.6]) in time
bin 0–10 min.
- Frequency of rearing [n] in time bins 0–10 min (F(1,6) = 14.1,
p = 0.01, MVEH = 44, [95% CI: 38.9,49.1], MIN−DA = 28.3;
[95% CI: 23.2, 33.4]) and 11–20 min (F(1,6) = 6.2, p = 0.047,
MVEH = 20.9 [95% CI: 15.5,26.2], MIN−DA = 10 [95% CI:
4.7, 15.3]). The effect was less pronounced on the duration
of rearing (0–10 min) and frequency of rearing (11–20 min).
Means and adjusted 95% confidence intervals are depicted
in Figures 3A–E (traveled distance: Figure 3A, velocity:
Figure 3B, frequency of entries into center: Figure 3C,
duration of rearing: Figure 3D, frequency of rearing:
Figure 3E).
IN-DA application significantly increased the following
behaviors in comparison to VEH: duration of head-shoulder
motility [s] (F(1,6) = 6.3, p = 0.046, MVEH = 35.9 [95% CI:
14, 57.9], MIN−DA = 80.8 [95% CI: 58.9, 102.8]), duration
(F(1,6) = 6.7, p = 0.042, MVEH = 113.5 [95% CI: 61.2, 165.7],
MIN−DA = 223.8 [95% CI: 171.6, 276.1]) and mean duration
(F(1,6) = 7.6, p = 0.033, MVEH = 14.2 [95% CI: 6.3, 22],
MIN−DA = 31.9 [95% CI: 24.1, 39.8]) of sitting [total: with
or without head-shoulder motility, s] in time bin 0–10 min.
The effects (illustrated by the error bars) were relatively small.
Means and adjusted 95% confidence intervals are shown in
Figures 4A–C (duration of head-shoulder motility: Figure 4A,
duration of sitting: Figure 4B, mean duration of sitting:
Figure 4C).
The fact that IN-DA yielded significant results only when
IN-DA followed VEH, can be interpreted in terms of the
variability of difference scores, i.e., only when the VEH treatment
was not preceded by IN-DA, the trend of the difference was
clear enough to produce a significant result. The largest effects
were found in four behaviors, which were reduced after IN-DA
treatment: traveled distance in time bin 11–20 min (reduced by
25%, or 361 cm, relative toMVEH), velocity in time bin 11–20 min
(reduced by 25%, or 0.6 cm/s, relative to MVEH), frequency of
entries into the center zone in time bin 0–10 min (reduced by
69%, or 4.7 entries, relative to MVEH), and frequency of rearing
in time bin 0–10 min (reduced by 36%, or 15.7 rearing sequences,
relative toMVEH).
Correlations Between Neostriatal DAT
Binding and Behaviors
Correlations After IN-DA Treatment Independent of
Order of Treatment (n = 12)
There was a significant inverse relationship between the
striatocerebellar ratio and the duration of head-shoulder
motility, min 11–20, after IN-DA treatment: rs = −0.587, 95%
BCa CI [−0.913, −0.011], p = 0.045 (Figure 5). Apparently, a
higher release of DA (leading to a higher reduction of DAT
binding) after IN-DA, predicts a longer duration of head-
shoulder motility.
Correlations After VEH Treatment Independent of
Order of Treatment (n = 12)
After VEH treatment, the striatocerebellar ratio correlated
negatively with the mean duration of head-shoulder motility
from min 0–10 (rs =−0.72, BCa CI [−0.978,−0.208], p = 0.008)
and with the mean duration of rearing, min 0–10 (rs = −0.699,
BCa CI [−0.935,−0.213], p = 0.011). Thus, presumably, a higher
release of DA (leading to a higher reduction of DAT binding)
after VEH treatment predicts a longer duration of both head-
shoulder motility and rearing behavior.
DISCUSSION
The major results of this work are: (1) that intranasally
applied DA reduced DAT binding in the neostriatum, thus
demonstrating a central action and indicating enhanced DA
availability; and (2) DAT binding upon intranasal vehicle
application was higher when preceded by intranasal
DA treatment, suggestive of Pavlovian conditioning of the
DA response at the DA transporter.
Neostriatal DAT Binding
Challenge with 3 mg/kg IN-DA significantly reduced neostriatal
DAT binding relative to IN-VEH. Cerebellar radioactivity
concentrations did not differ between IN-DA and VEH,
indicating that no confounding effects were exerted on
radioligand accumulation, for instance, by affecting cerebral
perfusion.
Neostriatal DAT binding can be altered by treatment with
compounds that increase synaptic DA levels in healthy animals
as well as in Parkinsonian patients and in animal models of PD
with subtotal DAergic depletion (for reviews, see Winogrodzka
et al., 2005; Nikolaus et al., 2016). The present effects of
IN-DA are consistent with previous in vivo and ex vivo findings
obtained in rats after treatment with L-DOPA (Gnanalingham
and Robertson, 1994; Dresel et al., 1998; Sossi et al., 2010;
Nikolaus et al., 2013, 2014). L-DOPA is a DA precursor and
increases the efflux of DA (for review, see Misu et al., 1996);
therefore, the reduction of DAT binding can be interpreted
in terms of an increase in levels of DA in the synaptic cleft.
Application of DA into the nostrils of anesthetized rats has
previously been shown to increase neostriatal DA levels for at
least 2 h by as much as 250% (de Souza Silva et al., 2008). These
findings suggest that the striatal DA transporter is targeted by
either a direct local action of the intranasally applied DA in the
synaptic cleft, or by an indirect action involving the stimulation
of DA synthesis or release, or even by remote effects elsewhere.
The possibility of up-regulation of DAT binding sites at the
presynaptic terminals in response to an increase in DA release
is unlikely, since IN-DA decreased DAT binding. Moreover, DA
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FIGURE 3 | Behaviors in the open field reduced after IN-DA (vs. VEH as first treatment, n = 7). (A) Traveled distance [cm], 11–20 min. (B) Velocity [cm/s],
11–20 min. (C) Frequency of entries into center zone [n], 0–10 min. (D) Duration of rearing [s], 0–10 min. (E) Frequency of rearing [n], 0–10 and 11–20 min. Means,
adjusted 95% CI of means.
levels are likely to have exceeded the capacity of available binding
sites at the time [123I]FP-CIT was administered.
The Ki value of [123I]FP-CIT amounts to 3.5 nM under
competition with GBR12909 (Neumeyer et al., 1996). For
DA, Ki values between 0.59 nM and 19 nM were reported
using various WIN 35,065 analogs as competitors (Kotian
et al., 1996). However, also Ki values in the micromolar range
were obtained when unlabeled DA was used as a competitor
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FIGURE 4 | Behaviors in the open field enhanced after IN-DA (vs. VEH as first treatment, n = 7). (A) Duration of head-shoulder motility [s], 0–10 min.
(B) Duration of sitting [s], 0–10 min. (C) Mean duration of sitting [s], 0–10 min. Means, adjusted 95% CI of means.
(e.g., Lee et al., 1996). This allows for a tentative estimation of
binding relations at the presynaptic terminal. If the affinities of
exogenous and endogenous ligands lie within the same order of
magnitude, the observed 17% decrease of [123I]FP-CIT binding
should reflect a just as high increase of synaptic DA. Interestingly,
the in vivo microdialysis findings of de Souza Silva et al.
(2008) showed a 250% increase of endogenous DA at about
30 min after IN-DA administration. This result suggests that
the affinity of [123I]FP-CIT for the DAT is at least one order of
magnitude higher than the affinity of DA with a 17% decrease
of [123I]FP-CIT binding, reflecting an increase of synaptic DA by
about 10- to 15-fold.
The mechanisms by which intranasal DA is transported
to the brain from the nasal mucosa are barely understood.
Unilaterally applied intransal [3H]DA has been shown to be
carried to the ipsilateral olfactory bulb in rodents, likely via
the olfactory pathway (Dahlin et al., 2000, 2001). However,
various mechanisms of transport from the nose to the brain,
including the trigeminal nerves have been proposed (for review,
see Tayebati et al., 2013). IN-DA applied in the same dose as in
our present study was found to increase the release of DA in both,
the nucleus accumbens and striatum of rats, implying both, the
mesocorticolimbic and nigrostriatal DA systems (de Souza Silva
et al., 2008). The present finding of a decrease in DAT binding
in the dorsal striatum after IN-DA treatment significantly adds
to our understanding of the central effects of IN-DA, although
it has not been determined which DA receptors are responsible
for its behavioral actions in the brain, nor whether pre- and
postsynaptic receptors are directly or indirectly activated by the
nasally applied DA.
Pavlovian Conditioning of Neural DA
Response?
DAT binding in response to VEH administration differed
depending on whether VEH preceded followed the application
of IN-DA. Striatal DAT binding was significantly lower (and
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DA levels presumably higher) when IN-DA precede VEH, than
vice versa. This result can be interpreted in terms of Pavlovian
drug conditioning, whereby in the open field, the handling
and nasal injection procedure acquired conditioned stimulus
properties that led to enhanced release of DA subsequent to the
unconditioned DA action of IN-DA and the resulting decrease of
exogenous radioligand binding to the striatal DAT. Comparable
evidence for conditioned psychostimulant effects at the level
of the DAT has not been reported before. Although these
differential binding effects dependent on order of presentation
could potentially have other causes besides classical conditioning
of the drug effects (see below) and require confirmation with
adequate control experiments, the possibility of such an action
justifies our tentative interpretation.
It should be noted that IN-DA, like most psychostimulants,
is likely to have affective, i.e., rewarding properties, although
IN-DA has not yet been tested for its potentially rewarding
effects. It is well known that cues associated with rewards,
including drugs of abuse, such as cocaine, opioids and alcohol
can acquire motivational properties and serve as incentives
(Robinson et al., 2014). During Pavlovian conditioning of a
tone CS with food UCS, DA release in the ventral striatum
increased during acquisition of conditioning and decreased
during extinction (Sunsay and Rebec, 2014; Biesdorf et al.,
2015). Similarly, Ostlund et al. (2014) found increased DA
release in the nucleus accumbens triggered by the presentation
of a cue that had been paired with cocaine reward. In fact,
the mechanisms that underlie Pavlovian drug conditioning
in general are likely to involve dopaminergic mechanisms
(Sparks et al., 2014; Lopez et al., 2015), and the nucleus
accumbens and dorsal striatum is thought to play a focal
role in such conditioning (Darvas et al., 2014). Reward-
predictive cues were found to evoke responses of neurons
in the NAc (Ambroggi et al., 2011) and changes in striatal
DA are well known to reflect cue-associated expectations of
reward contingencies (prediction errors; Sutton and Barto, 1981;
Schultz, 2010). DA concentration within the NAc core and shell
were also found to increase during acquisition of a Pavlovian
cocaine-cue association (Aragona et al., 2009). Within the NAc
shell, cue-evoked DA release developed during conditioning
to morphine (Bassareo et al., 2007). Signaling by extracellular
signal-regulated kinase (ERK) has also been shown to play a
role in Pavlovian psychostimulant conditioning (Lu et al., 2006).
One-trial induced Pavlovian conditioned behavioral response
to cocaine has been shown to persist for at least 21 days in
rats (McDougall et al., 2014). Such results lend credence to
an interpretation of our results in terms of Pavlovian drug
conditioning to IN-DA.
Our results have obvious relevance to the understanding of
the well know placebo responses in Parkinsonian patients to
medication and deep-brain stimulation. Expectation of positive
outcome can enhance beneficial behavioral effects of subthalamic
nucleus (STN) stimulation (Keitel et al., 2013). Placebo treatment
was also found to decrease neuronal activity in the STN
of Parkinsonian patients (Benedetti et al., 2004, 2016). Most
relevant to our results are the findings of evidence of DA release
in the striatum of PD patients to placebo using competition
for [11C]raclopride binding measured by positron emission
tomography (de la Fuente-Fernández et al., 2001; Lidstone
et al., 2010). The decrease in striatal binding found after saline
injection (placebo) presumably reflects increased DA binding
to D2 receptors. Our results support these findings in the
rat and provide evidence for placebo action on the DAT.
It has been proposed that the release of DA may underlie
placebo effects in general (de la Fuente-Fernández and Stoessl,
2002).
Behavioral Effects
The behavioral findings below are consistent with the hypothesis
of a conditioned central increase in release of DA. IN-DA
treatment yielded significant differences in certain behaviors
in comparison with VEH treatment only when VEH preceded
IN-DA. The effects were particularly prominent in four behaviors
that were decreased by IN-DA treatment, namely traveled
distance, velocity, frequency of entries into the center zone and
frequency of rearing.
In the animals treated with IN-DA before VEH, these
behaviors did not decrease in comparison with VEH, suggesting
DA conditioned behavioral effects as a likely cause, i.e., the
normal behavioral response to VEH could have been masked
or modified as a result of Pavlovian conditioning of the
unconditioned response to the preceding IN-DA. Such an
interpretation is consistent with a large literature describing
Pavlovian conditioned behavioral responses and sensitization to
psychoactive drugs, such as cocaine and amphetamine (Carey
et al., 2014), and particularly with the results of McDougall
et al. (2014), who found one-trial induced cocaine conditioned
activity, which persisted for at least 21 days in rats. This
interpretation is also consistent with the evidence above for a
Pavlovian conditioned DA response to VEH when VEH was
preceded by IN-DA.
The reduction of motor and exploratory parameters after
IN-DA treatment is comparable with findings on rats obtained
after L-DOPA challenge (5 and 10 mg/kg i.p.) in the same
apparatus (Nikolaus et al., 2014). The findings are also consistent
with reports of reduced behavioral activity after administration
of this DA precursor in moderate doses (McDevitt and Setler,
1981). Our finding of reduced behavioral activity after IN-DA,
seems to contradict previous findings of increased locomotor
activity after the same IN-DA dose (de Souza Silva et al.,
2008). The discrepancy may be accounted for by differences in
procedure: in the latter study (de Souza Silva et al., 2008), rats
had been pre-exposed to the open field for 30 min prior to
the IN-DA or VEH trials, whereas in the present study animals
were not subjected to a habituation trial prior to intranasal
challenge. Accordingly, Buddenberg et al. (2008) found that IN-
DA stimulated locomotor activity in a familiar, but not novel,
open field. The administration of IN-DA during the prepuberal
period in endogenously hyperactive rats also led to reduced
motor activity in the adult (Ruocco et al., 2014).
Striatal DAT binding was significantly reduced after IN-DA
relative to the VEH condition, reflecting the expected elevation
of synaptic DA activity after its nasal application, as also
shown by in vivo microdialysis (de Souza Silva et al., 2008).
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FIGURE 5 | Correlations between striatocerebellar ratio and behaviors observed after IN-DA or VEH. Duration of head-shoulder motility [s], 11–20 min,
mean duration of head-shoulder motility [s], 0–10 min and mean duration of rearing [s], 0–10 min.
Attenuated behavioral response to repeated exposure to the same
environment can be a consequence of behavioral habituation.
Thus, the attenuated behaviors found when IN-DA followed
VEH, could also reflect habituation. Since such habituation
depends on a memory for an encountered environment, it is
possible that IN-DA facilitated recognition of the open field,
leading to enhanced habituation and attenuated behavioral
activation. A possible memory-enhancing effect of IN-DA is in
line with previous findings of facilitated object-place memory in
rats by IN-DA application (Trossbach et al., 2014). DA is well
known to play a major role in associative learning (for review, see
Beninger, 1983), and specifically in working memory in humans
(Luciana and Collins, 1997) and rats (Chao et al., 2013). Likely
rewarding properties of IN-DA could be related to its behavioral
action. Affective properties could also potentially interact with
aversive or other effects of any control procedures (the carrier,
handling, etc) and result in differences in behaviors observed
after IN-DA vs. VEH.
Also in animals treated with VEH before IN-DA, the IN-DA
treatment was followed by an increase in duration of sitting and
duration of head-shoulder motility as compared to the VEH
condition. These effects can be considered in relation to the
reduction in motor and exploratory behaviors described above.
A significant inverse relationship was found between the
neostriatal DAT binding and the duration of head-shoulder
motility after IN-DA treatment and duration of head-shoulder
motility and rearing after VEH treatment. For all three behaviors,
lower values of exogenous ligand binding to the DAT (higher
DA action) were associated with elevated expression of the
particular behavior. Presumably, more availability of DA (leading
to a higher reduction of DAT binding) after IN-DA, predicts a
longer duration of head-shoulder motility, whereas a higher level
of DA after VEH predicts a longer duration of head-shoulder
motility and rearing. Reduced horizontal activity along with an
increase in duration of rearing has been reported before Ruocco
et al. (2014). Rearing behavior is related to exploration, attention
to novelty and arousal level (Sadile, 1996). Rearing behavior
has been shown to correlate with amount of in vivo release of
DA (Biesdorf et al., 2015). Our results support such a role of
dopaminergic neurotransmission in the expression of rearing,
based on an inverse relationship between [123I] FP-CIT binding
and DA binding.
CONCLUSION
The results: (a) demonstrate a central action of IN-DA on
the DAT in the dorsal striatum and thereby extend our
understanding of the central mechanisms by which nasal
DA application can influence behavior. An action of IN-DA
on the availability of DA in the dorsal striatum is of high
importance in light of the potential application of IN-DA as an
antiparkinsonian agent (Pum et al., 2009). The action of IN-
DA on DAT binding in the dorsal striatum is congruent with
the IN-DA-induced DA release found previously in this site (de
Souza Silva et al., 2008); (b) The results also provide first evidence
of a Pavlovian conditioned DA response at the level of the DAT.
Given that Pavlovian incentive conditioning is considered to be
a mechanism responsible for the development and maintenance
of addictive behaviors (Bassareo et al., 2007; Carey et al., 2014;
Everitt, 2014), the evidence that such conditioning influences
DAT binding suggests the DAT as a potential pharmacological
target to influence this process. Our result also supports findings
of Pavlovian conditioned DA release to placebo treatment in
Parkinsonian patients and provide an animal model for further
mechanistic study of such processes.
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